Operating
Non-Cash Lease Expense
Neurocrine Biosciences Non-Cash Lease Expense decreased by 59.1% to $2.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.5%, from $7.20M to $2.70M.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ3 2024
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests an expansion of the company's physical footprint or equipment leasing arrangements.
Detailed definition
This reflects the non-cash amortization of right-of-use assets associated with operating leases under accounting standar...
Peer comparison
Standard for all companies reporting under modern lease accounting standards.
Metric ID:
operating_lease_expenseHistorical Data
5 periods
| Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $300.00K | $7.20M | $7.10M | $6.60M | $2.70M |
| QoQ Change | — | >999% | -1.4% | -7.0% | -59.1% |
| YoY Change | — | — | — | >999% | -62.5% |
Range$300.00K – $7.20M
CAGR+800.0%
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak3 quarters decline
Non-Cash Lease Expense at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's non-cash lease expense?
- Neurocrine Biosciences (NBIX) reported non-cash lease expense of $2.70M in Q1 2026.
- How has Neurocrine Biosciences's non-cash lease expense changed year-over-year?
- Neurocrine Biosciences's non-cash lease expense decreased by 62.5% year-over-year, from $7.20M to $2.70M.
- What does non-cash lease expense mean?
- The non-cash accounting charge for the use of leased assets.